Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by TIEMO KLISCH and AKASH PATEL.
TIEMO KLISCH
Connection Strength
4.701
AKASH PATEL
  1. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc Natl Acad Sci U S A. 2019 10 22; 116(43):21715-21726.
    View in: PubMed
    Score: 0.633
  2. PD-L1 positivity predicts a unique hyperaggressive tumor group within MenG C meningiomas. JNCI Cancer Spectr. 2026 Mar 03; 10(2).
    View in: PubMed
    Score: 0.247
  3. Integrated Clinical Genetic Analysis Reveals Transcriptional Neurotransmitter Receptor Dysregulation in Meningiomas Causing Seizure. Neurosurgery. 2026 Feb 12.
    View in: PubMed
    Score: 0.246
  4. Integrated Clinical Genetic Analysis of Meningiomas Causing Bony Hyperostosis Shows More Severe Clinical Course and Overexpression of Secreted Pro-Osteogenic Factors. Neurosurgery. 2025 Apr 30; 97(4):842-852.
    View in: PubMed
    Score: 0.233
  5. Role of NF2 Mutation in the Development of Eleven Different Cancers. Cancers (Basel). 2024 Dec 29; 17(1).
    View in: PubMed
    Score: 0.227
  6. Aggressive human MenG C meningiomas have a molecular counterpart in canines. Acta Neuropathol. 2024 02 20; 147(1):42.
    View in: PubMed
    Score: 0.214
  7. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023 12; 29(12):3067-3076.
    View in: PubMed
    Score: 0.210
  8. Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers. J Neurooncol. 2023 Jun; 163(2):397-405.
    View in: PubMed
    Score: 0.204
  9. Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathol. 2023 04; 145(4):501-503.
    View in: PubMed
    Score: 0.199
  10. XCVATR: detection and characterization of variant impact on the Embeddings of single -cell and bulk RNA-sequencing samples. BMC Genomics. 2022 Dec 20; 23(1):841.
    View in: PubMed
    Score: 0.198
  11. Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci Adv. 2022 02 04; 8(5):eabm6247.
    View in: PubMed
    Score: 0.186
  12. Racial and Socioeconomic Disparities in Patients With Meningioma: A Retrospective Cohort Study. Neurosurgery. 2022 01 01; 90(1):114-123.
    View in: PubMed
    Score: 0.185
  13. Predictors of postoperative seizure outcome in supratentorial meningioma. J Neurosurg. 2022 Aug 01; 137(2):515-524.
    View in: PubMed
    Score: 0.184
  14. Identification of novel fusion transcripts in meningioma. J Neurooncol. 2020 Sep; 149(2):219-230.
    View in: PubMed
    Score: 0.169
  15. Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma. Cancers (Basel). 2020 Jun 05; 12(6).
    View in: PubMed
    Score: 0.166
  16. The Role of Merlin/NF2 Loss in Meningioma Biology. Cancers (Basel). 2019 Oct 24; 11(11).
    View in: PubMed
    Score: 0.159
  17. Newly Diagnosed Optic Pathway Glioma During Pregnancy. World Neurosurg. 2019 Jul; 127:58-62.
    View in: PubMed
    Score: 0.152
  18. Jak2-mediated phosphorylation of Atoh1 is critical for medulloblastoma growth. Elife. 2017 11 23; 6.
    View in: PubMed
    Score: 0.139
  19. Intraventricular Cavernomas of the Third Ventricle: Report of 2 Cases and a Systematic Review of the Literature. World Neurosurg. 2017 Sep; 105:935-943.e3.
    View in: PubMed
    Score: 0.135
  20. The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patients. Acta Neurochir (Wien). 2026 Apr 06.
    View in: PubMed
    Score: 0.062
  21. Fractionated radiotherapy adjuvant to surgery of WHO-2 meningioma with and without gross total resection: a multicenter, retrospective cohort study of 1,452 patients. J Neurooncol. 2026 Feb 09; 176(3):201.
    View in: PubMed
    Score: 0.061
  22. Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification. Nat Commun. 2025 Jul 02; 16(1):6024.
    View in: PubMed
    Score: 0.059
  23. NF2 loss-of-function and hypoxia drive radiation resistance in grade 2 meningiomas. J Natl Cancer Inst. 2025 Jun 01; 117(6):1175-1187.
    View in: PubMed
    Score: 0.059
  24. Multiomic and clinical analysis of multiply recurrent meningiomas reveals risk factors, underlying biology, and insights into evolution. Sci Adv. 2024 10 25; 10(43):eadn4419.
    View in: PubMed
    Score: 0.056
  25. Correction to: Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data. J Neurooncol. 2024 Jul; 168(3):525.
    View in: PubMed
    Score: 0.055
  26. Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data. J Neurooncol. 2024 Jul; 168(3):515-524.
    View in: PubMed
    Score: 0.055
  27. Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome. Cell Genom. 2024 Jun 12; 4(6):100566.
    View in: PubMed
    Score: 0.055
  28. The importance of considering competing risks in recurrence analysis of intracranial meningioma. J Neurooncol. 2024 Feb; 166(3):503-511.
    View in: PubMed
    Score: 0.053
  29. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Res Sq. 2023 Mar 20.
    View in: PubMed
    Score: 0.050
  30. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 2023 03 14; 25(3):520-530.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.